Open AccessEfficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
Author(s) -
Nadler Jp,
Berger Ds,
Gary Blick,
Cimoch Pj,
Cohen Cj,
Greenberg Rn,
Hicks Cb,
Hoetelmans Rm,
Iveson Kj,
Jayaweera Ds,
Anthony Mills,
Mathieu Peeters,
P. Ruane,
Peter Shalit,
Schräder,
Steven M. Smith,
Steinhart Cr,
Melanie Thompson,
Vingerhoets Jh,
E Voorspoels,
Doug Ward,
Brian Woodfall
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32805e8776
Subject(s) - etravirine , enfuvirtide , tolerability , reverse transcriptase inhibitor , ritonavir , medicine , lopinavir , viral load , adverse effect , population , pharmacology , virology , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , environmental health , antigen , gp41 , epitope
TMC125-C223 is an open-label, partially blinded, randomized clinical trial to evaluate the efficacy and safety of two dosages of etravirine (TMC125), a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant HIV-1.